Brought to you by

Gilead pays $65mm cash to buy EpiTherapeutics
02 Oct 2020
Executive Summary
Gilead Sciences Inc. paid $65mm cash to acquire privately held epigenetics company EpiTherapeutics APS.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Acquisition
- Full Acquisition
- Intra-Biotech Deal
- Payment Includes Cash
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Related Companies
Advertisement